Figure 2. ¹¹C-DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide) time–activity curves for various tissues and tumour in the pre-phase I study group. The time–activity curves were corrected for decay and normalised for the injected activity per body surface area. Kindly reproduced with permission from: Saleem A, Harte R, Matthews J, Osman S, Brady F, Luthra S, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001;19:1421–9.